[Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case].
Yuka Kitamura, Noriaki Sakakura, Tatsuo Uchida, Motokazu Suyama
Abstract
Yuka Kitamura, Noriaki Sakakura, Tatsuo Uchida, Motokazu Suyama
Abstract
Although gefitinib is known to possess an effect inducing apoptosis against lung cancer, it is not clear how clinically effective it is in this regard in patients with lung cancer. Therefore, we tried to reduce its administration from every to every other day in a 73-year-old woman in good condition over 5 years after the recurrence of lung cancer. As a result, her CEA serum level then commenced to increase to the abnormal range within a month. Apoptosis induced by gefitinib was thought not sufficient to kill all lung cancer cells even though well controlled by it for a long period.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Although gefitinib is known to possess an effect inducing apoptosis against lung cancer, it is not clear how clinically effective it is in this regard in patients with lung cancer. Therefore, we tried to reduce its administration from every to every other day in a 73-year-old woman in good condition over 5 years after the recurrence of lung cancer. As a result, her CEA serum level then commenced to increase to the abnormal range within a month. Apoptosis induced by gefitinib was thought not sufficient to kill all lung cancer cells even though well controlled by it for a long period.
Key concepts: Gefitinib, Lung cancer, Medicine, Apoptosis, Lung, Oncology, Internal medicine, Cancer